Citadel Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.38M | Buy |
+633,354
| New | +$4.88M | ﹤0.01% | 4563 |
|
|
2025
Q4 | – | Sell |
-263,806
| Closed | -$1.45M | – | 14181 |
|
|
2025
Q3 | $1.32M | Buy |
263,806
+116,009
| +78% | +$537K | ﹤0.01% | 6942 |
|
|
2025
Q2 | $698K | Sell |
147,797
-100,309
| -40% | -$439K | ﹤0.01% | 7847 |
|
|
2025
Q1 | $1.14M | Sell |
248,106
-132,979
| -35% | -$620K | ﹤0.01% | 6682 |
|
|
2024
Q4 | $1.83M | Buy |
381,085
+238,650
| +168% | +$1.15M | ﹤0.01% | 5826 |
|
|
2024
Q3 | $668K | Sell |
142,435
-5,001
| -3% | -$26.8K | ﹤0.01% | 7653 |
|
|
2024
Q2 | $833K | Sell |
147,436
-577,803
| -80% | -$2.98M | ﹤0.01% | 6975 |
|
|
2024
Q1 | $2.98M | Buy |
725,239
+106,233
| +17% | +$425K | ﹤0.01% | 4798 |
|
|
2023
Q4 | $2.61M | Sell |
619,006
-65,147
| -10% | -$263K | ﹤0.01% | 4893 |
|
|
2023
Q3 | $2.96M | Buy |
684,153
+48,639
| +8% | +$270K | ﹤0.01% | 4513 |
|
|
2023
Q2 | $4.19M | Sell |
635,514
-382,687
| -38% | -$2.45M | ﹤0.01% | 3927 |
|
|
2023
Q1 | $6.91M | Buy |
1,018,201
+469,872
| +86% | +$3.3M | ﹤0.01% | 3298 |
|
|
2022
Q4 | $4.05M | Buy |
548,329
+460,594
| +525% | +$4.49M | ﹤0.01% | 4219 |
|
|
2022
Q3 | $867K | Buy |
87,735
+52,058
| +146% | +$550K | ﹤0.01% | 7303 |
|
|
2022
Q2 | $389K | Buy |
+35,677
| New | +$370K | ﹤0.01% | 9201 |
|
|
2021
Q4 | – | Sell |
-39,200
| Closed | -$683K | – | 14826 |
|
|
2021
Q3 | $672K | Sell |
39,200
-69,324
| -64% | -$1.21M | ﹤0.01% | 9170 |
|
|
2021
Q2 | $2.33M | Sell |
108,524
-63,625
| -37% | -$1.14M | ﹤0.01% | 6211 |
|
|
2021
Q1 | $2.58M | Sell |
172,149
-71,826
| -29% | -$1.16M | ﹤0.01% | 5789 |
|
|
2020
Q4 | $3.21M | Sell |
243,975
-700,360
| -74% | -$8.43M | ﹤0.01% | 4485 |
|
|
2020
Q3 | $9.12M | Buy |
944,335
+50,284
| +6% | +$537K | ﹤0.01% | 2392 |
|
|
2020
Q2 | $10.2M | Buy |
894,051
+592,275
| +196% | +$6.71M | ﹤0.01% | 2190 |
|
|
2020
Q1 | $3.13M | Sell |
301,776
-21,658
| -7% | -$269K | ﹤0.01% | 3396 |
|
|
2019
Q4 | $5.31M | Sell |
323,434
-90,007
| -22% | -$1.36M | ﹤0.01% | 3006 |
|
|
2019
Q3 | $5.49M | Buy |
413,441
+361,974
| +703% | +$5.04M | ﹤0.01% | 2984 |
|
|
2019
Q2 | $725K | Sell |
51,467
-73,937
| -59% | -$1.18M | ﹤0.01% | 6237 |
|
|
2019
Q1 | $2.31M | Sell |
125,404
-46
| -0% | -$1.05K | ﹤0.01% | 4222 |
|
|
2018
Q4 | $3.28M | Sell |
125,450
-296,849
| -70% | -$6.98M | ﹤0.01% | 3389 |
|
|
2018
Q3 | $9.69M | Buy |
422,299
+280,979
| +199% | +$5.74M | ﹤0.01% | 2129 |
|
|
2018
Q2 | $2.69M | Buy |
141,320
+63,906
| +83% | +$1.07M | ﹤0.01% | 3641 |
|
|
2018
Q1 | $1.3M | Sell |
77,414
-54,186
| -41% | -$907K | ﹤0.01% | 4404 |
|
|
2017
Q4 | $2M | Sell |
131,600
-658,785
| -83% | -$9.78M | ﹤0.01% | 3632 |
|
|
2017
Q3 | $14.1M | Buy |
790,385
+291,867
| +59% | +$4.88M | 0.01% | 1318 |
|
|
2017
Q2 | $8.13M | Buy |
498,518
+53,833
| +12% | +$776K | 0.01% | 1622 |
|
|
2017
Q1 | $6.22M | Buy |
444,685
+288,502
| +185% | +$4.11M | 0.01% | 1833 |
|
|
2016
Q4 | $2.49M | Buy |
156,183
+102,160
| +189% | +$1.64M | ﹤0.01% | 2697 |
|
|
2016
Q3 | $899K | Buy |
54,023
+36,531
| +209% | +$492K | ﹤0.01% | 3982 |
|
|
2016
Q2 | $196K | Sell |
17,492
-43,251
| -71% | -$419K | ﹤0.01% | 5853 |
|
|
2016
Q1 | $508K | Sell |
60,743
-49,072
| -45% | -$403K | ﹤0.01% | 4384 |
|
|
2015
Q4 | $1.02M | Sell |
109,815
-24,585
| -18% | -$245K | ﹤0.01% | 3538 |
|
|
2015
Q3 | $1.52M | Buy |
134,400
+28,107
| +26% | +$344K | ﹤0.01% | 3285 |
|
|
2015
Q2 | $1.35M | Buy |
106,293
+61,346
| +136% | +$662K | ﹤0.01% | 3574 |
|
|
2015
Q1 | $418K | Sell |
44,947
-36,730
| -45% | -$415K | ﹤0.01% | 5198 |
|
|
2014
Q4 | $1.17M | Buy |
81,677
+80,137
| +5,204% | +$948K | ﹤0.01% | 3572 |
|
|
2014
Q3 | $16K | Sell |
1,540
-35,110
| -96% | -$460K | ﹤0.01% | 7593 |
|
|
2014
Q2 | $593K | Sell |
36,650
-33,869
| -48% | -$451K | ﹤0.01% | 4165 |
|
|
2014
Q1 | $1.15M | Sell |
70,519
-311,118
| -82% | -$4.42M | ﹤0.01% | 3263 |
|
|
2013
Q4 | $4.74M | Buy |
381,637
+321,275
| +532% | +$3.23M | 0.01% | 1730 |
|
|
2013
Q3 | $662K | Sell |
60,362
-32,294
| -35% | -$345K | ﹤0.01% | 3522 |
|
|
2013
Q2 | $749K | Buy |
+92,656
| New | +$624K | ﹤0.01% | 3446 |
|
Other funds holding VNDA
ACM
VCM
Citadel Advisors's VNDA Position: Q1 2026 in Review
Citadel Advisors opened a new position in Vanda Pharmaceuticals (VNDA) in Q1 2026: 633,354 shares worth $4.38M. The stake represents ﹤0.01% of the portfolio and ranks #4563 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in VNDA as recently as Q3 2025.
Citadel Advisors first reported a position in VNDA in Q2 2013 and has held it in 49 quarters since. The position peaked at $14.1M in Q3 2017. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.
- Citadel Advisors held 633,354 shares of Vanda Pharmaceuticals worth $4.38M as of Q1 2026.
- Vanda Pharmaceuticals was a new Citadel Advisors position in Q1 2026.
- Vanda Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4563 holding.
- Citadel Advisors first reported a position in Vanda Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
- Citadel Advisors's Vanda Pharmaceuticals position peaked at $14.1M in Q3 2017.
- 170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.